stockrow
Friday 6 November 2026
Export CALC’s income statement to Excel — free account
CalciMedica Inc.
CALC Healthcare Biotechnology
- EPS
- −12.5%
- Free cash flow
- +31.4%
- Total debt
- +8.24%
Quarter to June 2026, against a year earlier
1.36
0.06
+4.62%
Follow CALC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 2 | 2 | 0.0% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (28) | (37) | (28) | (36) | (8) | (34) | (14) | (30) | (21) | +0.6% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | (28) | (37) | (28) | (36) | (8) | (34) | (14) | (30) | (21) | +0.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1,803.87) | (2,338.37) | (367.64) | (118.34) | (555.80) | (38.30) | (6.10) | (9.85) | (6.75) | (52.5%) | ||||||
| Cash flow | — | — | (1,556.75) | (1,655.45) | (339.30) | (104.06) | (716.89) | (28.68) | (9.40) | (7.05) | (5.59) | (53.7%) | ||||||
| Capex | — | — | (80.61) | (32.09) | (10.83) | (1.61) | (0.24) | (0.09) | 0.00 | (0.01) | 0.01 | (72.6%) | ||||||
| Free cash flow | — | — | (1,637.36) | (1,687.54) | (350.13) | (105.68) | (717.13) | (28.76) | (9.41) | (7.06) | (5.58) | (54.1%) | ||||||
| Book value | — | — | (3,685.10) | (5,460.05) | 1,003.03 | 214.81 | (4,347.80) | 9.09 | 6.41 | (2.21) | 1.61 | (65.3%) | ||||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | +107.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (28) | (31) | (32) | (31) | (12) | (26) | (21) | (21) | (19) | (4.0%) | |||||
| Capex | — | — | (1) | (1) | (1) | 0 | 0 | 0 | 0 | 0 | 0 | (43.2%) | ||||||
| Free cash flow | — | — | (30) | (32) | (33) | (32) | (12) | (26) | (21) | (21) | (19) | (4.7%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 8 | 24 | 92 | 63 | (3) | 8 | 16 | 10 | 16 | +3.5% | |||||
| Net debt | — | — | 66 | 95 | (95) | (64) | 4 | (11) | (19) | (3) | (9) | n/m | ||||||
| Shareholders’ equity | — | — | (67) | (103) | 95 | 65 | (71) | 8 | 14 | (7) | 6 | (28.1%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (111.83) | (150.81) | (48.75) | (41.92) | (25.24) | (442.35) | (85.68) | (177.10) | (110.10) | (65.3) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (1,660.52) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 38.52 | 51.95 | 850.15 | (44.83) | 291.10 | 108.82 | (121.42) | (761.02) | (365.70) | (799.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 24 | 31 | 27 | 8 | 14 | 14 | 16 | — | (6.5%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
CalciMedica Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $9.3M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $9.1M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $8.9M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | |
| BLRX BioLineRx Ltd. | $8.8M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LEXX Lexaria Bioscience Corp. | $8.8M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $9.1M | — | — | −8.70% | — | −38.96% | 39.97% | 0.00% |
Pay and ownership Proxy statement filed 23 July 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 895.41k | 2.44m | 230.00 |
| 2024 | 1.66m | 1.46m | 124.00 |
Ownership
Directors and executive officers, together
28.25%
Alafi Capital Company, LLC
16.63%
Fred Middleton
9.07%
Entities affiliated with Sanderling Ventures
8.66%
Entities affiliated with Bering Partners II, L.P.
7.27%
Evgeny Zaytsev, M.D., Ph.D.
7.27%
Robert N. Wilson
5.69%
A. Rachel Leheny, Ph.D.
5.41%
Eric W. Roberts
5.29%
CVI Investments, Inc.
5.06%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement